New Clinical Imaging Modalities in Prostate Cancer

Hematology/Oncology Clinics of North America

Volumn 20, Issue 4, 2006, Pages 811-830

  Ross, Robert ^a   Harisinghani, Mukesh ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Center for Molecular Imaging Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; NANOPARTICLE; TRACER;

ANTIBODY LABELING; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCEMENT; CYCLOTRON; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; IMAGING SYSTEM; LYMPH NODE; LYMPH NODE METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TRANSRECTAL ULTRASONOGRAPHY; ULTRASOUND;

DIAGNOSTIC IMAGING; HUMANS; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY;

EID: 33746190660     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.03.009     Document Type: Review

References (104)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
2. Scher H.I., Eisenberger M., D'Amico A.V., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22 3 (2004) 537-556
3. Scher H.I., and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 3 (2000) 323-327
4. Coffield K.S., Speights V.O., Brawn P.N., et al. Ultrasound detection of prostate cancer in postmortem specimens with histological correlation. J Urol 147 3 Pt 2 (1992) 822-826
5. Kuligowska E., Barish M.A., Fenlon H.M., et al. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology 220 3 (2001) 757-764
6. Naughton C.K., Miller D.C., Mager D.E., et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 164 2 (2000) 388-392
7. Stewart C.S., Leibovich B.C., Weaver A.L., et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 1 (2001) 86-91 [discussion 91-82]
8. Yu K.K., and Hricak H. Imaging prostate cancer. Radiol Clin North Am 38 1 (2000) 59-85 [viii.]
9. Purohit R.S., Shinohara K., Meng M.V., et al. Imaging clinically localized prostate cancer. Urol Clin North Am 30 2 (2003) 279-293
10. Leventis A.K., Shariat S.F., Utsunomiya T., et al. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. Prostate 46 4 (2001) 281-288
11. Frauscher F., Klauser A., Halpern E.J., et al. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 357 9271 (2001) 1849-1850
12. Blomley M., and Cosgrove D. Microbubble echo-enhancers: a new direction for ultrasound?. Lancet 349 9069 (1997) 1855-1856
13. Frauscher F., Halpern E.J., and Klauser A. Accuracy of gray-scale and color Doppler US and serum markers as predictors of prostate carcinoma. Radiology 223 1 (2002) 282-283 author reply 283-284
14. Frauscher F., Klauser A., Volgger H., et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 167 4 (2002) 1648-1652
15. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 17 (2005) 2095-2101
16. Adusumilli S., and Pretorius E.S. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 20 3 (2002) 192-210
17. Buonocore E., Hesemann C., Pavlicek W., et al. Clinical and in vitro magnetic resonance imaging of prostatic carcinoma. AJR Am J Roentgenol 143 6 (1984) 1267-1272
18. Hersh M.R., Knapp E.L., and Choi J. Newer imaging modalities to assess tumor in the prostate. Cancer Control 11 6 (2004) 353-357
19. Engelbrecht M.R., Jager G.J., Laheij R.J., et al. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12 9 (2002) 2294-2302
20. Tempany C.M., Zhou X., Zerhouni E.A., et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 192 1 (1994) 47-54
21. Brassell S.A., Krueger W.R., Choi J.H., et al. Correlation of endorectal coil magnetic resonance imaging of the prostate with pathologic stage. World J Urol 22 4 (2004) 289-292
22. Bernstein M.R., Cangiano T., D'Amico A., et al. Endorectal coil magnetic resonance imaging and clinicopathologic findings in T1c adenocarcinoma of the prostate. Urol Oncol 5 3 (2000) 104-107
23. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 14 6 (1996) 1770-1777
24. Cheng G.C., Chen M.H., Whittington R., et al. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA < or = 10, and clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 55 1 (2003) 64-70
25. D'Amico A.V., Whittington R., Malkowicz B., et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 164 3 Pt 1 (2000) 759-763
26. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55 4 (2000) 572-577
27. Brown G., Macvicar D.A., Ayton V., et al. The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 50 9 (1995) 601-606
28. Engelbrecht M.R., Huisman H.J., Laheij R.J., et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229 1 (2003) 248-254
29. Hara N., Okuizumi M., Koike H., et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62 2 (2005) 140-147
30. Ito H., Kamoi K., Yokoyama K., et al. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br J Radiol 76 909 (2003) 617-624
31. Jager G.J., Ruijter E.T., van de Kaa C.A., et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203 3 (1997) 645-652
32. Namimoto T., Morishita S., Saitoh R., et al. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 22 3 (1998) 239-245
33. Ogura K., Maekawa S., Okubo K., et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 57 4 (2001) 721-726
34. Padhani A.R., Gapinski C.J., Macvicar D.A., et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55 2 (2000) 99-109
35. Coakley F.V., Qayyum A., and Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170 6 Pt 2 (2003) S69-S75 [discussion S75-66]
36. Kurhanewicz J., Vigneron D.B., Hricak H., et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198 3 (1996) 795-805
37. Kurhanewicz J., Vigneron D.B., and Nelson S.J. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2 1-2 (2000) 166-189
38. Scheidler J., Hricak H., Vigneron D.B., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 2 (1999) 473-480
39. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 2 (2000) 400-404
40. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 1 (2002) 91-97
41. Yu K.K., Scheidler J., Hricak H., et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213 2 (1999) 481-488
42. Prando A., Kurhanewicz J., Borges A.P., et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236 3 (2005) 903-910
43. Zakian K.L., Eberhardt S., Hricak H., et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging-initial results. Radiology 229 1 (2003) 241-247
44. Hosseinzadeh K., and Schwarz S.D. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 20 4 (2004) 654-661
45. Bloch B.N., Rofsky N.M., Baroni R.H., et al. 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils: initial experience (1). Acad Radiol 11 8 (2004) 863-867
46. Futterer J.J., Scheenen T.W., Huisman H.J., et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 39 11 (2004) 671-680
47. Sosna J., Pedrosa I., Dewolf W.C., et al. MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad Radiol 11 8 (2004) 857-862
48. Sosna J., Rofsky N.M., Gaston S.M., et al. Determinations of prostate volume at 3-Tesla using an external phased array coil: comparison to pathologic specimens. Acad Radiol 10 8 (2003) 846-853
49. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 24 (1999) 1781-1788
50. Manyak M.J., and Javitt M.C. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol 16 3 (1998) 145-152
51. Harisinghani M.G., Saini S., Weissleder R., et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 172 5 (1999) 1347-1351
52. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175 2 (1990) 494-498
53. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175 2 (1990) 489-493
54. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499
55. Harisinghani M.G., and Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med 1 3 (2004) e66
56. Harisinghani M.G., Saksena M.A., Hahn P.F., et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?. AJR Am J Roentgenol 186 (2006) 144-148
57. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231 2 (2004) 379-385
58. Silverman J.M., and Krebs T.L. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 168 2 (1997) 379-385
59. Chan T.W., and Kressel H.Y. Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging 1 5 (1991) 503-511
60. Coakley F.V., Hricak H., Wefer A.E., et al. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219 3 (2001) 817-821
61. Coakley F.V., Teh H.S., Qayyum A., et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233 2 (2004) 441-448
62. Steinborn M.M., Heuck A.F., Tiling R., et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23 1 (1999) 123-129
63. Hricak H., Schoder H., Pucar D., et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 30 5 (2003) 616-634
64. Algra P.R., Bloem J.L., Tissing H., et al. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 11 2 (1991) 219-232
65. Tombal B., Rezazadeh A., Therasse P., et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65 2 (2005) 178-187
66. Antoch G., Vogt F.M., Freudenberg L.S., et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290 24 (2003) 3199-3206
67. Ballon D., Watts R., Dyke J.P., et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med 52 6 (2004) 1234-1238
68. Daldrup-Link H.E., Franzius C., Link T.M., et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177 1 (2001) 229-236
69. Ghanem N., Uhl M., Brink I., et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 55 1 (2005) 41-55
70. Eustace S., Tello R., DeCarvalho V., et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 169 6 (1997) 1655-1661
71. Seltzer M.A., Barbaric Z., Belldegrun A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162 4 (1999) 1322-1328
72. Kahn D., Williams R.D., Haseman M.K., et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16 1 (1998) 284-289
73. Levesque P.E., Nieh P.T., Zinman L.N., et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51 6 (1998) 978-984
74. Kahn D., Austin J., Miller S., et al. IN-111 capromab pendetide MAB scan predicts response to radiotherapy to the prostate fossa in men with tumor recurrence following radical prostatectomy: 3-year follow-up. J Urol 161 4S (1999) 239
75. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21 9 (2003) 1715-1721
76. Wilkinson S., and Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 172 1 (2004) 133-136
77. Hamaoka T., Madewell J.E., Podoloff D.A., et al. Bone imaging in metastatic breast cancer. J Clin Oncol 22 14 (2004) 2942-2953
78. Dotan Z.A., Bianco Jr. F.J., Rabbani F., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 9 (2005) 1962-1968
79. Gates G.F. SPECT bone scanning of the spine. Semin Nucl Med 28 1 (1998) 78-94
80. Even-Sapir E., Martin R.H., Barnes D.C., et al. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology 187 1 (1993) 193-198
81. Savelli G., Maffioli L., Maccauro M., et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 45 1 (2001) 27-37
82. Han L.J., Au-Yong T.K., Tong W.C., et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 25 6 (1998) 635-638
83. Even-Sapir E., Metser U., Mishani E., et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47 2 (2006) 287-297
84. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46 8 (2005) 1356-1367
85. Shvarts O., Han K.R., Seltzer M., et al. Positron emission tomography in urologic oncology. Cancer Control 9 4 (2002) 335-342
86. Kumar R., Zhuang H., and Alavi A. PET in the management of urologic malignancies. Radiol Clin North Am 42 6 (2004) 1141-1153 [ix.]
87. Schoder H., and Larson S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34 4 (2004) 274-292
88. de Jong I.J., Pruim J., Elsinga P.H., et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44 3 (2003) 331-335
89. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43 2 (2002) 181-186
90. Liu I.J., Zafar M.B., Lai Y.H., et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 1 (2001) 108-111
91. Effert P.J., Bares R., Handt S., et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 3 (1996) 994-998
92. Sanz G., Robles J.E., Gimenez M., et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84 9 (1999) 1028-1031
93. Oyama N., Akino H., Suzuki Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 12 (1999) 623-629
94. Heicappell R., Muller-Mattheis V., Reinhardt M., et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36 6 (1999) 582-587
95. Kato T., Tsukamoto E., Kuge Y., et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29 11 (2002) 1492-1495
96. Kotzerke J., Volkmer B.G., Glatting G., et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 1 (2003) 25-30
97. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 1 (1999) 31-35
98. Turlakow A., Larson S.M., Coakley F., et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45 3 (2001) 235-244
99. Schoder H., Herrmann K., Gonen M., et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11 13 (2005) 4761-4769
100. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46 6 (2005) 983-995
101. Yeh S.D., Imbriaco M., Larson S.M., et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23 6 (1996) 693-697
102. Shreve P.D., Grossman H.B., Gross M.D., et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199 3 (1996) 751-756
103. Morris M.J., Akhurst T., Osman I., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59 6 (2002) 913-918
104. Morris M.J., Akhurst T., Larson S.M., et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11 9 (2005) 3210-3216